title: Early cryptococcal meningitis following treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.
authors.forename: Tony
authors.initials: T
authors.lastname: Marchand
authors.forename: Matthieu
authors.initials: M
authors.lastname: Revest
authors.forename: Pierre
authors.initials: P
authors.lastname: Tattevin
authors.forename: Sylviane
authors.initials: S
authors.lastname: Chevrier
authors.forename: Elsa
authors.initials: E
authors.lastname: Poullot
authors.forename: Thierry
authors.initials: T
authors.lastname: Lamy
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000302:isolation & purification*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D016919:Meningitis, Cryptococcal / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D000069283:Rituximab; D013997:Time Factors; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000935:Antifungal Agents; D000069283:Rituximab; D000666:Amphotericin B; D003520:Cyclophosphamide; D005437:Flucytosine; D014740:Vidarabine; C024352:fludarabine